{
  "id": "5c7a4ed5d774d04240000008",
  "type": "list",
  "question": "What are the advantages of liquid biopsy in NSCLC?",
  "ideal_answer": "Liquid biopsy reflected spatial and temporal heterogeneity of the tumor under treatment pressure.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29885479",
    "http://www.ncbi.nlm.nih.gov/pubmed/25137181",
    "http://www.ncbi.nlm.nih.gov/pubmed/27285610",
    "http://www.ncbi.nlm.nih.gov/pubmed/30174936"
  ],
  "snippets": [
    {
      "text": "Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137181",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We report for the first time that the CellSearch System coupled with NGS is a very sensitive and specific diagnostic tool for EGFR mutation analysis in CTC preparations with potential clinical impact.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this respect, mutation analysis of circulating tumor cells (CTCs) may be desirable since they may provide real-time information on patient's disease status.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27285610",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These plasma-isolated exosomes can be used as a non-invasive and repeatable way for the detection and follow-up of these biomarkers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27285610",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Liquid biopsy reflected spatial and temporal heterogeneity of the tumor under treatment pressure. We provide the proof-of-concept that the complementary use of ctDNA and ctcDNA represents a reliable, minimally invasive and dynamic tool for a more comprehensive view of tumor evolution.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30174936",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29885479",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29885479",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "real-time information, non-invasive, reflects spatiotemporal heterogeneity"
}